Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Receivables (2019 - 2025)

Biodesix's Receivables history spans 7 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Receivables rose 5.03% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $9.0 million, up 5.03%, while the annual FY2025 figure was $9.0 million, 5.03% up from the prior year.
  • Receivables reached $9.0 million in Q4 2025 per BDSX's latest filing, down from $12.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $18.4 million in Q1 2021 to a low of $2.8 million in Q3 2021.
  • Average Receivables over 5 years is $7.2 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Receivables: crashed 79.45% in 2022, then soared 145.88% in 2024.
  • A 5-year view of Receivables shows it stood at $3.7 million in 2021, then soared by 38.54% to $5.1 million in 2022, then skyrocketed by 51.61% to $7.7 million in 2023, then increased by 12.03% to $8.6 million in 2024, then rose by 5.03% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Receivables are $9.0 million (Q4 2025), $12.7 million (Q3 2025), and $7.5 million (Q2 2025).